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IL: interleukin
PAPA: pyogenic arthritis, pyoderma
gangrenosum, and acne
PASH: pyoderma gangrenosum, acne, and
suppurative hidradenitis
PG: pyoderma gangrenosum
TNF: tumor necrosis factor
UC: ulcerative colitisINTRODUCTION
Pyoderma gangrenosum (PG) is a rare, inflamma-
tory, and necrotizing disease that belongs to the
group of neutrophilic dermatosis.1-3 The pathogen-
esis of PG remains unknown. In the last 2 years,
some researchers found a significant increase in
interleukin (IL)-1b and in the IL-1b receptor in skin
samples of PG patients.
Most PG cases respond to immunomodulators
and immunosuppressants. However, there are no
clear gold standards for PG treatment. Systemic
corticosteroids and cyclosporine are considered
first-line treatments. Azathioprine, mycophenolate
mofetil, cyclophosphamide, and methotrexate are
considered second-line therapies.4-10
Antietumor necrosis factor-a (TNF-a) biological
agents show efficacy for a wide range of inflamma-
tory conditions, including inflammatory bowel dis-
ease, rheumatoid arthritis, and psoriasis. Several
studies report PG being successfully treated with
infliximab (including 1 randomized, controlled
trial11), etanercept, and adalimumab. Infliximab is a
chimeric IgG monoclonal antibody that blocks the
inflammatory cytokine TNF-a. Adalimumab is a fully
human monoclonal antibody IgG1 against TNF-a.
Etanercept is a human TNF receptor fusion protein
that inhibits the binding of TNF-a to TNF receptors
on cells’ surfaces.
Because a significant contribution of IL-1 to the
pathogenesis of PG has been confirmed, biologic
agents that inhibit IL-1 represent a therapeutic option
in PG.9-14
Our patient had ulcerative PG for 24 years. Her
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treatment with canakinumab, the lesions were
completely healed in 7 months.CLINICAL CASE
A 54-year-old female patient had a history of
ulcerative colitis (UC) and ulcerative PG on her lower
limbs that was diagnosed in 1991 and an 11-year
treatment course with systemic corticosteroids
and cyclosporine. Her PG became refractory to this
treatment, so she was subsequently treated with
infliximab, 5 mg/kg doses, in 3 infusions in weeks 0,
2, and 6. Pain immediately diminished, and the
re-epithelialization of lesions was complete in
5 months. After 2 disease-free years, the patient
relapsed with pyoderma gangrenosum associated
with aggravated UC. She restarted treatment with
infliximab, adding azathioprine (150 mg/d). Lesions
re-epithelialized within 10 months.
In 2011, she relapsed with both pyoderma
gangrenosum and UC. She restarted treatment with
infliximab. UC was controlled, but the cutaneous
lesions did not improve. We switched the therapy toJAAD Case Reports 2016;2:366-8.
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Fig 1. Evolution of the ulcer in inner left lower leg. A, Before treatment. B, Two weeks after the
last doses of canakinumab. C, 6 months after the beginning of treatment.
Fig 2. Evolution of the ulcer in inner right lower leg. A, Before treatment. B, Two weeks after
the last doses of canakinumab. C, None months after the beginning of treatment.
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wk thereafter). After 4 months, lesions hadworsened
with pain, bleeding, and exposure of tendons (Figs 1,
A and 2,A). Treatment was switched to canakinumab
(150 mg once per month for 3 doses by subcutane-
ous injection). Two weeks after the first dose, the
ulcers were filled with granulation tissue and were
no longer painful (Fig 1, B). Two weeks after the
third and last dose, the patient presented with
complete re-epithelialization of the lesions in the
right leg and a 70% reduction of the ulcers in the left
leg (Figs 1, C and 2, B). After 7 months, re-
epithelialization was complete.
COMMENTS
The pathogenesis of PG remains unknown.
Dinarello et al9 classified PAPA (pyogenic arthritis,
pyoderma gangrenosum, and acne) and PASH (pyo-
derma gangrenosum, acne, and suppurative hidra-
denitis) syndromes as autoinflammatory disorders in
which a genetic predisposition favors an increase in
inflammatory cytokines that belong to the innate
immune system (such as IL-1b).9 In these diseases,inflammasomes activate caspase-1 and cleave the
proeIL-1b into its active form. IL-1b activates endo-
thelial cells, leading to an increased expression of
adhesion molecules that stimulate the recruitment of
neutrophils. This cytokine also increases the average
life of the neutrophils.9
In 2013, 2 articles commented on the successful use
of anti IL-1b monoclonal antibodies in a patient with
PAPA-like syndrome and in a patient who had PG
associated with hidradenitis suppurativa; both dis-
eases were refractory to systemic corticosteroids.10,12
Marzano et al15 measured the levels of inflamma-
tory cytokines in the histopathology of 16 PG
patients and compared themwith the histopathology
of healthy patients. In PG patients, they observed an
increase in TNF-a and IL-17 and their receptors and a
significant increase in IL-1b.15
Kolios et al14 quantified cytokine mRNA levels by
performing real-time quantitative polymerase chain
reaction on the skin samples of 7 PG patients and
compared them with healthy skin and dermatitis
samples. They found a significant increase in IL-1b
and in the IL-1b receptor in PG patients. They also
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They showed no significant increase in TNF-a, IFN-
g, IL-36, or IL-12.14
Research advances in the role of IL-1b in pyoderma
gangrenosum’s pathogenesis published in interna-
tional journals in the last 3 years support the use of
the biologic agent anti IL-1b in PG that is resistant to
systemic corticosteroids or immunomodulators.
Anakinra was the first biologic antieIL-1 available
on the market. It is a recombinant nonglycosylated
protein of the IL-1 receptor antagonist. It blocks the
biologic activity of IL-1a and IL-1b by competitively
inhibiting the binding of IL-1 to their receptor. It can
be administered subcutaneously or intravenously. A
daily dose is recommended. Because of its daily use,
anakinra could be a problem in patients who have
positive pathergy. Rilonacept is a dimeric fusion
protein that joins IL-1b and IL-a, thereby obstructing
them. Rilonacept is used on a weekly basis.9,13
Canakinumab is a fully humanized monoclonal
IgG1 antieIL-1b antibody that binds to human IL-1b
and neutralizes its activity by selectively blocking its
interaction with IL-1 receptors. It is given subcuta-
neously every 1 or 2 months.9,13 Canakinumab may
be the best treatment for PG that is refractory to
classic therapy. This judgment is based on physio-
pathology and on the risk of pathergy.
This is our first experience with canakinumab.
Successful resolution showed that it might be an
effective and well-tolerated treatment for patients
with PG whose disease is refractory to classic therapy
and supports recent discoveries on the prime role of
IL-1b in this dermatosis. There are only a few reports
onPG treatedwith canakinumaband, at present, there
is not enough evidence to draw a firm conclusion.
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